Dexcom, Inc. (DXCM)

$134.3

+0.44

(+0.33%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Dexcom, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 741.5M → 1.03B (in $), with an average increase of 10.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, 48.6M → 256.3M (in $), with an average increase of 38.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 31.7% return, outperforming this stock by 19.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 32.3%

Performance

  • $133.60
    $135.95
    $134.30
    downward going graph

    0.52%

    Downside

    Day's Volatility :1.73%

    Upside

    1.21%

    downward going graph
  • $74.75
    $142.00
    $134.30
    downward going graph

    44.34%

    Downside

    52 Weeks Volatility :47.36%

    Upside

    5.42%

    downward going graph

Returns

PeriodDexcom, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
5.03%
-0.7%
4.2%
6 Months
59.13%
6.6%
17.8%
1 Year
12.55%
3.7%
29.0%
3 Years
36.23%
14.0%
11.6%

Highlights

Market Capitalization
52.6B
Book Value
$5.37
Earnings Per Share (EPS)
1.31
PE Ratio
104.21
PEG Ratio
2.53
Wall Street Target Price
151.05
Profit Margin
14.95%
Operating Margin TTM
20.97%
Return On Assets TTM
6.41%
Return On Equity TTM
25.78%
Revenue TTM
3.6B
Revenue Per Share TTM
9.38
Quarterly Revenue Growth YOY
26.900000000000002%
Gross Profit TTM
1.9B
EBITDA
783.7M
Diluted Eps TTM
1.31
Quarterly Earnings Growth YOY
1.81
EPS Estimate Current Year
1.75
EPS Estimate Next Year
2.23
EPS Estimate Current Quarter
0.43
EPS Estimate Next Quarter
0.28

Analyst Recommendation

Buy
    89%Buy
    10%Hold
    0
    0%Sell
Based on 28 Wall street analysts offering stock ratings for Dexcom, Inc.(by analysts ranked 0 to 5 stars)
Based on 28 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
25
24
24
Hold
3
3
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 12.47%

Current $134.30
Target $151.05

Company Financials

FY18Y/Y Change
Revenue
1.0B
↑ 43.58%
Net Income
-127.1M
↑ 153.19%
Net Profit Margin
-12.32%
↓ 5.33%
FY19Y/Y Change
Revenue
1.5B
↑ 43.08%
Net Income
101.1M
↓ 179.54%
Net Profit Margin
6.85%
↑ 19.17%
FY20Y/Y Change
Revenue
1.9B
↑ 30.54%
Net Income
493.6M
↑ 388.23%
Net Profit Margin
25.62%
↑ 18.77%
FY21Y/Y Change
Revenue
2.4B
↑ 27.08%
Net Income
154.7M
↓ 68.66%
Net Profit Margin
6.32%
↓ 19.3%
FY22Y/Y Change
Revenue
2.9B
↑ 18.84%
Net Income
341.2M
↑ 120.56%
Net Profit Margin
11.73%
↑ 5.41%
FY23Y/Y Change
Revenue
3.6B
↑ 24.49%
Net Income
541.5M
↑ 58.7%
Net Profit Margin
14.95%
↑ 3.22%
Q3 FY22Q/Q Change
Revenue
769.6M
↑ 10.54%
Net Income
101.2M
↑ 98.82%
Net Profit Margin
13.15%
↑ 5.84%
Q4 FY22Q/Q Change
Revenue
815.2M
↑ 5.93%
Net Income
91.8M
↓ 9.29%
Net Profit Margin
11.26%
↓ 1.89%
Q1 FY23Q/Q Change
Revenue
741.5M
↓ 9.04%
Net Income
48.6M
↓ 47.06%
Net Profit Margin
6.55%
↓ 4.71%
Q2 FY23Q/Q Change
Revenue
871.3M
↑ 17.51%
Net Income
115.9M
↑ 138.48%
Net Profit Margin
13.3%
↑ 6.75%
Q3 FY23Q/Q Change
Revenue
975.0M
↑ 11.9%
Net Income
120.7M
↑ 4.14%
Net Profit Margin
12.38%
↓ 0.92%
Q4 FY23Q/Q Change
Revenue
1.0B
↑ 6.1%
Net Income
256.3M
↑ 112.34%
Net Profit Margin
24.78%
↑ 12.4%
FY18Y/Y Change
Total Assets
1.9B
↑ 111.92%
Total Liabilities
1.3B
↑ 158.45%
FY19Y/Y Change
Total Assets
2.4B
↑ 25.0%
Total Liabilities
1.5B
↑ 20.73%
FY20Y/Y Change
Total Assets
4.3B
↑ 79.14%
Total Liabilities
2.5B
↑ 62.92%
FY21Y/Y Change
Total Assets
4.9B
↑ 13.36%
Total Liabilities
2.6B
↑ 6.01%
FY22Y/Y Change
Total Assets
5.4B
↑ 10.86%
Total Liabilities
3.3B
↑ 24.8%
FY23Y/Y Change
Total Assets
6.3B
↑ 16.19%
Total Liabilities
4.2B
↑ 28.71%
Q3 FY22Q/Q Change
Total Assets
4.9B
↓ 6.1%
Total Liabilities
3.1B
↑ 3.82%
Q4 FY22Q/Q Change
Total Assets
5.4B
↑ 10.05%
Total Liabilities
3.3B
↑ 6.02%
Q1 FY23Q/Q Change
Total Assets
5.5B
↑ 2.3%
Total Liabilities
3.3B
↑ 0.71%
Q2 FY23Q/Q Change
Total Assets
6.8B
↑ 23.66%
Total Liabilities
4.7B
↑ 43.78%
Q3 FY23Q/Q Change
Total Assets
6.6B
↓ 3.29%
Total Liabilities
4.3B
↓ 8.3%
Q4 FY23Q/Q Change
Total Assets
6.3B
↓ 5.03%
Total Liabilities
4.2B
↓ 3.06%
FY18Y/Y Change
Operating Cash Flow
123.2M
↑ 33.91%
Investing Cash Flow
-139.8M
↓ 3.19%
Financing Cash Flow
710.4M
↑ 78.0%
FY19Y/Y Change
Operating Cash Flow
314.5M
↑ 155.28%
Investing Cash Flow
-1.0B
↑ 626.18%
Financing Cash Flow
10.7M
↓ 98.49%
FY20Y/Y Change
Operating Cash Flow
475.6M
↑ 51.22%
Investing Cash Flow
-1.0B
↑ 0.28%
Financing Cash Flow
912.1M
↑ 8424.3%
FY21Y/Y Change
Operating Cash Flow
442.5M
↓ 6.96%
Investing Cash Flow
-216.1M
↓ 78.77%
Financing Cash Flow
10.4M
↓ 98.86%
FY22Y/Y Change
Operating Cash Flow
669.5M
↑ 51.3%
Investing Cash Flow
-521.5M
↑ 141.32%
Financing Cash Flow
-552.5M
↓ 5412.5%
Q3 FY22Q/Q Change
Operating Cash Flow
293.2M
↑ 69.68%
Investing Cash Flow
229.3M
↓ 258.25%
Financing Cash Flow
-552.5M
↑ 12748.84%
Q4 FY22Q/Q Change
Operating Cash Flow
132.5M
↓ 54.81%
Investing Cash Flow
-194.1M
↓ 184.65%
Financing Cash Flow
-1000.0K
↓ 99.82%
Q1 FY23Q/Q Change
Operating Cash Flow
155.4M
↑ 17.28%
Investing Cash Flow
-186.7M
↓ 3.81%
Financing Cash Flow
11.2M
↓ 1220.0%
Q2 FY23Q/Q Change
Operating Cash Flow
190.3M
↑ 22.46%
Investing Cash Flow
-555.9M
↑ 197.75%
Financing Cash Flow
939.5M
↑ 8288.39%
Q3 FY23Q/Q Change
Operating Cash Flow
269.2M
↑ 41.46%
Investing Cash Flow
-179.5M
↓ 67.71%
Financing Cash Flow
-637.4M
↓ 167.84%

Technicals Summary

Sell

Neutral

Buy

Dexcom, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dexcom, Inc.
Dexcom, Inc.
-0.64%
59.13%
12.55%
36.23%
368.49%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dexcom, Inc.
Dexcom, Inc.
104.21
104.21
2.53
1.75
0.26
0.06
NA
5.37
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dexcom, Inc.
Dexcom, Inc.
Buy
$52.6B
368.49%
104.21
14.95%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • Vanguard Group Inc

    11.53%

  • BlackRock Inc

    8.49%

  • Baillie Gifford & Co Limited.

    4.29%

  • State Street Corporation

    4.20%

  • Capital Research Global Investors

    3.97%

  • Sands Capital Management, LLC

    3.91%

Company Information

founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.

Organization
Dexcom, Inc.
Employees
9500
CEO
Mr. Kevin Ronald Sayer
Industry
Health Technology

Discover More

FAQs